Loading patent…
AssigneesMUSC Foundation for Research Development, The Penn State Research Foundation
InventorsJames Norris, Gary Clawson, Caroline Westwater, David Schofield, Michael Schmidt, Brian Hoel, Joseph Dolan, Wei-Hua Pan
Estimating the term…
The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agents to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention. Specifically, the invention relates to the delivery of one or more toxic gene products, antisense RNAs, or ribozymes, or combination thereof. The invention provides a novel system by which multiple pathogenic targets may be simultaneously targeted to cause the death of a pathogen, or cell infected with a pathogen. Further, the invention has important implications in the eradication of drug-resistant bacterium and bacterial pathogens. The invention provides a novel system by which multiple targets may be simultaneously targeted to cause the death of a diseased cell. The invention also has important implications in the eradication of drug-resistant pathogens and drug-resistant diseased cells (such as cancer cells).
A recombinant nucleic acid comprising a nucleotide sequence encoding one or more antisense RNA operably linked to a pathogen-specific or tissue-specific promoter, wherein the antisense RNA comprises the sequence of DicF1, as presented in FIG. 2 (SEQ ID NO:3).
A recombinant nucleic acid comprising a nucleotide sequence encoding one or more toxic agents operably linked to a pathogen-specific or tissue-specific promoter, wherein the promoter is the LEASHI promoter (as presented in FIG. 1A, SEQ ID NO:1).
A recombinant nucleic acid comprising a nucleotide sequence encoding one or more toxic agents operably linked to a pathogen-specific or tissue-specific promoter, wherein the toxic agent is constructed into a sequence encoding a ribozyme cassette comprising one or more autocatalytically cleaving ribozyme sequence, and wherein the ribozyme cassette is pChop.
A recombinant nucleic acid comprising a nucleotide sequence encoding one or more toxic agents operably linked to a pathogen-specific or tissue-specific promoter, wherein the toxic agent is constructed into a sequence encoding a ribozyme cassette comprising one or more autocatalytically cleaving ribozyme sequence, and wherein the ribozyme cassette is pSnip.
A recombinant nucleic acid comprising a nucleotide sequence encoding one or more toxic agents operably linked to a pathogen-specific or tissue-specific promoter, wherein the toxic agent is constructed into a sequence encoding a ribozyme cassette comprising one or more autocatalytically cleaving ribozyme sequence, and wherein the ribozyme cassette is pClip.
A nucleic acid comprising the nucleotide sequence of the LEASHI promoter, as presented in FIG. 1B (SEQ ID NO.1).
A nucleic acid comprising the nucleotide sequence of DicF1, as presented in FIG. 2 (SEQ ID NO:3).
A recombinant nucleic acid comprising a nucleotide sequence encoding one or more toxic agents operably linked to a pathogen-specific or tissue-specific promoter, wherein the promoter is a modified rrnB promoter (as presented in FIG. 1B, SEQ ID NO:2).
Dependencies are inferred from the claim text.